WARRENDALE, Pa., Aug. 11 /PRNewswire/ -- MEDRAD, INC., announced today that the wireless version of its Continuum MR Infusion System has received U.S. Food and Drug Administration (FDA) 510(k) clearance.
The new Continuum Wireless MR Infusion System enables the clinician to control a patient's medication infusion during a magnetic resonance (MR) procedure from both inside and outside the scan room. When changes are needed, including flow rate, bolus, or to start or stop the infusion altogether, clinicians can control these parameters without interrupting the MRI scan with a new wireless remote display featuring a color touch screen. This option will increase workflow efficiencies and throughput while enhancing clinician confidence by enabling easy selection from up to nine IV stands, minimizing scan interruptions due to infusion changes and displaying all infusion parameters.
"The Continuum Wireless is designed to produce efficiency and boost throughput in MRI, but it also builds confidence in the patient care staff that control of a patient's medication is always nearby, especially when implemented for applications like pediatric sedation," said Joe Havrilla, senior vice president, MEDRAD MR Business Unit.
Continuum Wireless joins the Veris(R) MR Monitor as the second product to utilize MEDRAD's Certo(TM) MR Wireless Network.
The original Continuum MR Infusion System was introduced in 2002 as the first infusion system designed for the harsh electro-magnetic environment in MR. MEDRAD has designed an upgrade path to wireless for current Continuum users.
MEDRAD, INC., is a worldwide leading provider of medical devices and
services that enable and enhance imaging procedures of the human body. Used
in diagnostic imaging, MEDRAD's product offerings include a comprehensive
|SOURCE MEDRAD, INC.|
Copyright©2008 PR Newswire.
All rights reserved